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Aripiprazole increases the PKA signalling and expression of the GABAA receptor
and CREB1 in the nucleus accumbens of rats
Abstract
The GABAA receptor is implicated in the pathophysiology of schizophrenia and regulated by PKA
signalling. Current antipsychotics bind with D2-like receptors, but not the GABAA receptor. The cAMPresponsive element-binding protein 1 (CREB1) is also associated with PKA signalling and may be related
to the positive symptoms of schizophrenia. This study investigated the effects of antipsychotics in
modulating D2-mediated PKA signalling and its downstream GABAA receptors and CREB1. Rats were
treated orally with aripiprazole (0.75 mg/kg, ter in die (t.i.d.)), bifeprunox (0.8 mg/kg, t.i.d.), haloperidol
(0.1 mg/kg, t.i.d.) or vehicle for 1 week. The levels of PKA-Cα and p-PKA in the prefrontal cortex (PFC),
nucleus accumbens (NAc) and caudate putamen (CPu) were detected by Western blots. The mRNA levels
of Gabrb1, Gabrb2, Gabrb3 and Creb1, and their protein expression were measured by qRT-PCR and
Western blots, respectively. Aripiprazole elevated the levels of p-PKA and the ratio of p-PKA/PKA in the
NAc, but not the PFC and CPu. Correlated with this elevated PKA signalling, aripiprazole elevated the
mRNA and protein expression of the GABAA (β-1) receptor and CREB1 in the NAc. While haloperidol
elevated the levels of p-PKA and the ratio of p-PKA/PKA in both NAc and CPu, it only tended to increase
the expression of the GABAA (β-1) receptor and CREB1 in the NAc, but not the CPu. Bifeprunox had no
effects on PKA signalling in these brain regions. These results suggest that aripiprazole has selective
effects on upregulating the GABAA (β-1) receptor and CREB1 in the NAc, probably via activating PKA
signalling.
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Abstract
The GABAA receptor is implicated in the pathophysiology of schizophrenia and regulated by
PKA signalling. Current antipsychotics bind with D2-like receptors, but not the GABAA
receptor. The cAMP-responsive element-binding protein 1 (CREB1) is also associated with
PKA signalling and may be related to the positive symptoms of schizophrenia. This study
investigated the effects of antipsychotics in modulating D2-mediated PKA signalling and its
downstream GABAA receptors and CREB1. Rats were treated orally with aripiprazole
(0.75mg/kg, t.i.d. (ter in die)), bifeprunox (0.8mg/kg, t.i.d.), haloperidol (0.1mg/kg, t.i.d.) or
vehicle for 1 week. The levels of PKA-Cα and p-PKA in the prefrontal cortex (PFC), nucleus
accumbens (NAc) and caudate putamen (CPu) were detected by Western Blots. The mRNA
levels of Gabrb1, Gabrb2, Gabrb3 and Creb1, and their protein expression were measured by
qRT-PCR and Western Blots, respectively. Aripiprazole elevated the levels of p-PKA and the
ratio of p-PKA/PKA in the NAc, but not the PFC and CPu. Correlated with this elevated
PKA signalling, aripiprazole elevated the mRNA and protein expression of the GABAA (β-1)
receptor and CREB1 in the NAc. While haloperidol elevated the levels of p-PKA and the
ratio of p-PKA/PKA in both NAc and CPu, it only tended to increase the expression of the
GABAA (β-1) receptor and CREB1 in the NAc, but not the CPu. Bifeprunox had no effects
on PKA signalling in these brain regions. These results suggest that aripiprazole has selective
effects on up-regulating the GABAA (β-1) receptor and CREB1 in the NAc, probably via
activating PKA signalling.
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Introduction
Gamma-aminobutyric acid (GABA) is one of the major inhibitory neurotransmitters, and has
been reported to be involved in the pathophysiology of schizophrenia (see review Benes,
2015). The GABA receptor family consists of three classes of receptors – GABAA, GABAB
and GABAC; the GABAA receptor is widely distributed in the brain (Hendry et al., 1989).
Previous studies reported abnormal GABAA receptor density in various brain regions of
schizophrenia subjects, including the prefrontal cortex (PFC) (Dean et al., 1999, Ishikawa et
al., 2004), cingulate cortex (Benes et al., 1992), superior temporal gyrus (Deng and Huang,
2006) and hippocampus (Benes et al., 1997). Antipsychotic drug administration also affects
GABAA receptors. For example, a 6-month treatment with haloperidol increased the density
of GABAA receptor binding of [3H]-muscimol in the caudate putamen (CPu), the core of the
nucleus accumbens (NAc), while reducing it in the parietal and temporal cortex; both
haloperidol and clozapine increased the bindings of GABAA receptors in the anterior
cingulate and infralimbic cortex, respectively (Zink et al., 2004). Skilbeck and colleagues
(2007) reported that the total population of GABAA receptors was increased by 1-week
treatment with haloperidol and olanzapine; however, antipsychotic effects diminished in the
longer treatment groups. Additionally, McLeod et al. (2008) found that administration with
haloperidol decreased the GABAA binding site in the thalamus but increased binding sites in
the hypothalamus. It is worth noting that none of the antipsychotics directly binds with
GABAA receptors, which raises a critical question: which pathway(s) do antipsychotics act
on to affect the GABAA receptors?

All current antipsychotics act on D2-like receptors (including D2, D3 and D4) to achieve their
therapeutic effects (Kapur and Mamo, 2003). Typical antipsychotic drugs (e.g. haloperidol)
can potently block D2-like receptors, being effective in alleviating the positive symptoms of
2

schizophrenia (such as delusions, hallucination, disordered speech and behaviours etc.), but
inducing severe extrapyramidal side-effects (EPS; such as acute dyskinesias and dystonic
reactions, tardive dyskinesia, and Parkinsonism etc.) (Kapur and Mamo, 2003). Furthermore,
although binding to multiple receptors (including serotonin 5-HT2A, 5-HT2C, muscarinic
receptors), the majority of the atypical antipsychotics (e.g. clozapine, olanzapine and
risperidone) also antagonise D2Rs (Kapur and Mamo, 2003). In recent years, partial agonists
for D2-like receptors were the focus of the new drug development. Aripiprazole is a
successful D2 partial agonist that possesses therapeutic effects in schizophrenia, with much
lower EPS side-effects (Mailman and Murthy, 2010). However, to date, all other partial
agonists, except aripiprazole, failed to achieve meaningful clinical efficacy for schizophrenia
or were discontinued due to tolerability and/or safety issues (Benkert et al., 1995, Lahti et al.,
1998). Recently, bifeprunox, a potent partial agonist for the dopamine D2 receptor, exhibited
therapeutic effects in clinical trials (Casey et al., 2008), but was still disapproved and
cancelled due to severe side effects (e.g. nausea) and unstable long-term therapeutic effects
(Casey et al., 2008, Lundbeck, 2009). Therefore, it is necessary to investigate the
pharmacological mechanism of aripiprazole by comparing it with other D2 partial agonists
(e.g. bifeprunox).

The G protein-dependent cAMP-PKA pathway is a major downstream signalling pathway of
D2-like receptors, in which activation of D2-like receptors inhibits the activity of adenylate
cyclase and synthesis of cAMP via the Gi protein, followed by the inhibition of PKA
signalling (Beebe, 1994). A post-mortem study found reduced PKA regulatory subunits in
schizophrenia patients (Tardito et al., 2000), indicating that PKA signalling may be related to
the pathophysiology of schizophrenia. In vivo studies have suggested that PKA signalling
may be involved in the clinical effects of antipsychotics. For example, acute haloperidol and
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olanzapine treatment can increase the expression of PKA catalytic subunits in the CPu in rats
(Turalba et al., 2004); another study indicated that haloperidol facilitated this signalling
(Kaneko et al., 1992); furthermore, the activity of the cAMP-PKA pathway and expression of
PKA regulatory subunits in the striatum were elevated after 3-week treatment with
haloperidol, whereas clozapine displayed opposite effects in various brain areas (Dwivedi et
al., 2002).

PKA kinase regulates several downstream substrates that are involved in the pathophysiology
of schizophrenia. The GABAA receptor can be regulated by D2-like receptor-mediated PKA
signalling (Connelly et al., 2013). In addition, cAMP-responsive element-binding protein
(CREB) is another PKA downstream substrate (Shaywitz and Greenberg, 1999). Novel
variants in the CREB gene have been identified in schizophrenic patients who have
experienced the positive symptoms of schizophrenia (Kawanishi et al., 1999). Previous
studies revealed that haloperidol increased phosphorylation levels of CREB in both in vivo
and in vitro studies (Konradi and Heckers, 1995, Pozzi et al., 2003, Yang et al., 2004). Both
amisulpride and clozapine can also induce the phosphorylation of CREB in vitro (Jeon et al.,
2015, Park et al., 2011). Therefore, we proposed that antipsychotic drugs may modulate
GABAA receptors and CREB1 activity through the PKA signalling pathway. The present
study investigated the effects of antipsychotics on the PKA downstream GABAA receptors,
and CREB1.

Methods
Animals and drug administration
Male Sprague-Dawley rats (aged 8 weeks) were obtained from the Animal Resource Centre
(Perth, Australia). After arrival, all rats were housed in individual cages under
4

environmentally controlled conditions (temperature 22°C, light cycle from 07:00 AM to
07:00 PM), with ad libitum access to water and standard laboratory chow diet. All
experimental procedures were approved by the Animal Ethics Committee (Application #:
AE11/02), University of Wollongong, and complied with the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes (2004). All animals were euthanised
using carbon dioxide. All efforts were made to minimise animal distress and prevent
suffering.

Before the drug administration commenced, the rats were fed with cookie dough (containing
sucrose 30.9%, corn starch 30.9%, casein 15.5%, minerals 8.4%, fibre 6.4%, gelatine 6.3%
and vitamins 1.6%) without drugs for 1 week to train them to self-administrate the drug. Then
rats were randomly assigned into one of the following drug groups (n = 6 / group) and orally
treated with cookie dough mixed with the drug powder: aripiprazole (0.75 mg/kg, t.i.d. (ter in
die); Otsuka, Japan), bifeprunox (0.8 mg/kg, t.i.d.; Otava, Ukraine), haloperidol (0.1 mg/kg,
t.i.d.; Sigma, Australia), or vehicle for 1 week. Water was added to achieve a dry-dough
consistency immediately prior to administration. Rats were offered cookies with drugs by a
metal spoon three times a day (at 06:00 AM, 02:00 PM and 10:00 PM) and observed to
ensure complete consumption of each pellet. These dosages were equivalent to the
recommended dosage in the clinic, and they were translated based on body surface area
according to the FDA guidelines for clinical trials (FDA, 2005, Reagan-Shaw et al., 2008).
This drug administration method has been well established in our laboratory (De Santis et al.,
2014, Deng et al., 2015). A 0.75 mg/kg aripiprazole dosage in rats is equivalent to ~7.5 mg in
humans (60 kg body weight), while 0.8 mg/kg bifeprunox and 0.1 mg/kg haloperidol is
equivalent to ~8 mg and ~1 mg respectively, all of which are within the used/recommended
clinical dosages (Casey et al., 2008, Emsley, 2009, Mace and Taylor, 2009). It was reported
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that aripiprazole and bifeprunox, at these dosages, had over 90% D2 receptor occupancy in rat
brains (Wadenberg, 2007), while haloperidol reached approximately 70% D2R occupancy
(Kapur et al., 2003, Naiker et al., 2006, Natesan et al., 2006). Furthermore, the dosages used
in this study have been shown to be physiologically and behaviourally effective in rodents
(Assie et al., 2006, De Santis et al., 2014, Han et al., 2009, Kesby et al., 2006, Wadenberg,
2007), whilst not causing EPS side-effects (Natesan et al., 2006, Wadenberg, 2007). After 1week administration, all rats were sacrificed between 10:00 AM and 12:00 PM to minimise
possible circadian-induced variation of protein expression. Brains were immediately removed,
frozen in liquid nitrogen and stored at -80°C until required.

Microdissection
Following a standard procedure used in our lab, discrete brain regions were collected using
brain microdissection puncture, which has been performed successfully (Pan et al., 2015).
Based on the brain atlas (Paxinos and Watson, 2005), three sections through the forebrain
(Bregma 3.30 to 4.20 mm) were dissected for the PFC; three sections through the striatum
(Bregma 1.00 to 2.20 mm) were dissected for the NAc and CPu, respectively. The three brain
regions were chosen because they are key brain areas involved in the effects of antipsychotics.
Tissue obtained was stored at -80°C until use.

Western Blots
The Western Blots procedures were described previously (Lian et al., 2014, Pan et al., 2015).
Tissue was homogenised with NP-40 cell lysis buffer (Invitrogen, Camarillo, CA, USA)
mixed with Protease Inhibitor Cocktail (Sigma-Aldrich, St Louis, MO, USA), βGlycerophosphate (Invitrogen) and phenylmethylsulfonylfluoride (Sigma-Aldrich). The
homogenised samples were centrifuged, and the supernatants were collected. Protein
6

concentrations of the supernatants were determined spectrophotometrically using the DC
Protein Assay (Bio-Rad, #500-0111). Samples containing 10 µg of protein were resolved by
10% SDS-PAGE gels, and then transferred electrophoretically to a polyvinylidene difluoride
membrane using Bio-Rad Midi Format 1-D Electrophoresis Systems. The membranes were
blocked by 5% skim milk and incubated in primary antibodies. Amersham Hyperfilm ECL
(GE Healthcare, #28-9068-36) was used to visualise the immunoreactive bands. The
immunoreactive signals were quantified using Bio-Rad Quantity One software. The data were
normalised to the corresponding actin levels. Experiments of Western Blots were performed
in duplicate to ensure consistency.

Two catalytic (Cα and Cβ) isoform of PKA subunits have been previously identified (Cadd
and McKnight, 1989). PKA-Cα expression was measured due to its highest expression in
brain tissues (Soberg et al., 2013, Uhler et al., 1986). Therefore, two antibodies for PKA
subunits were chosen in the present study: anti-PKA-Cα (1:1000; Santa Cruz, #SC-903) and
anti-phosphor-PKA-C (Thr197) (1:1000; Cell Signalling, #5661). Subunits of GABAA
receptors and CREB1 were examined using: anti-GABAA β-1 (1:1000; Abcam, #ab154822),
anti-GABAA β-2 (1:1000; Abcam, #ab156000), anti-GABAA β-3 (1:1000; Abcam, #ab98968)
and anti-CREB1 (1:1000; Abcam, #ab32515). Mouse anti-actin primary polyclonal antibody
(1:10000; Millipore, #MAB1501) were used to determine the actin levels. The secondary
antibodies used in this study were HRP-linked anti-rabbit IgG antibody (1:3000; Cell
Signalling, #7074) and HRP-linked anti-mouse IgG antibody (1:3000; Cell Signalling,
#7076).

RNA isolation and related quantitative real-time PCR
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Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to measure the
mRNA expression levels of Gabrb1, Gabrb2, Gabrb3 and Creb1 in the brain regions where
the PKA signalling was significantly affected by antipsychotic drug administration. The qRTPCR procedures were described previously (Liu et al., 2015). Briefly, PureLink® RNA Mini
Kit (Invitrogen Life Technologies, Carlsbad, CA, USA) was used to extract RNA. Firststrand cDNA was synthesised from RNA with Superscript® VILOTM cDNA Synthesis Kit
(Life Technologies, NSW, Australia) by incubation at 42 °C for 60 min. Then, each sample
cDNA was performed qRT-PCR in duplicate using TaqMan® Gene Expression Assays
(Applied Biosystems, Foster City, USA) on LightCycler® 480 (Roche, Penzberg, Germany).
The assay (Life Technologies, NSW, Australia) identifications of the target genes were
Gabrb1 (Rn00564146_m1), Gabrb2 (Rn00564149_m1), Gabrb3 (Rn00567029_m1) and
Creb1 (Rn00578828_g1). All gene expression levels were normalized relative to two
endogenous

control

genes

glyceraldehyde-3-phosphatedehydrogenase

(Rn01775763_g1) and β-actin (Rn00667869_m1).

(GAPDH)

The 2-ΔΔCT method was used to

calculate the results.

Statistics
All data were analysed using the SPSS Statistics v22.0 program. The data of both Western
Blots and qRT-PCR experiments were normalised by taking the average value of the control
group as 100% and expressed as mean ± S.E.M. The individual control value was also
normalised to the average of overall control experiments for statistical analysis. The
phosphorylated protein p-PKA was normalised by the levels of total PKA-Cα. Normality test
was performed to test data distribution. One-way analysis of variance (ANOVA) was
performed if the data was normally distributed, followed by Post-hoc Dunnett t test to
compare the control and each drug treatment group. Pearson's correlation test was used to
8

analyse the relationships among the measurements. Statistical significance was accepted
when p < 0.05.

Results
Antipsychotic drug effects on PKA signalling
PFC. The expression of PKA-Cα subunits in the PFC was significantly affected by 1-week
drug administration (F3,

20

= 3.723, p < 0.05). In comparison with the control group,

administration with aripiprazole induced a significant elevation in the protein levels of PKACα (123.6 ± 3.7%, p < 0.05) (Fig. 1A & 1D). However, no drug significantly affected the
levels of p-PKA and the ratio of p-PKA/PKA (Fig. 1A).

NAc. It was shown that antipsychotic drug administration had a significant effect on the
levels of p-PKA (F3, 20 = 13.123, p < 0.01) and the ratio of p-PKA/PKA (F3, 20 = 3.216, p <
0.05) in the NAc. It was further revealed that administration with both aripiprazole and
haloperidol was able to significantly elevate the levels of p-PKA (aripiprazole: 134.3 ± 7.0%,
p < 0.01; haloperidol: 140.6 ± 6.0%, p < 0.01) in the NAc (Fig. 1B & 1D). The ratio of pPKA/PKA was also significantly increased by administration with aripiprazole (118.0 ± 7.5%,
p < 0.05) and haloperidol (118.6 ± 3.8%, p < 0.05) (Fig. 1B).

CPu. In the CPu, drug administration significantly altered the protein levels of PKA-Cα (F3,
20

= 24.183, p < 0.01) and p-PKA (F3, 20 = 16.281, p < 0.01) and the ratio of p-PKA/PKA (F3,

20

= 20.043, p < 0.01). Post-hoc tests showed all three chemicals were able to significantly

elevate the expression of PKA-Cα in the CPu (aripiprazole: 159.3 ± 3.5%, p < 0.01;
bifeprunox: 126.7 ± 7.1%, p < 0.01; haloperidol: 125.0 ± 5.4%, p < 0.01). However, only
haloperidol significantly elevated the levels of p-PKA (+88.1%, p < 0.01) (Fig. 1C & 1D).
9

The ratio of p-PKA/PKA was significantly reduced by aripiprazole administration (61.0 ±
1.6%, p < 0.01), but increased by haloperidol administration (148.5 ± 12.4%, p < 0.01) (Fig.
1C).

Antipsychotic drug effects on mRNA and protein expression of GABAA subunits and
CREB1
Since significant antipsychotic drug effects on the activation of PKA signalling were
observed in the NAc and CPu, GABAA receptors and CREB1 were examined in these two
brain regions. The results showed that the mRNA expression levels of Gabrb1 (F3, 20 = 7.898,
p < 0.01) were significantly altered by antipsychotic drug administration in the NAc.
Furthermore, both aripiprazole and haloperidol administration up-regulated the mRNA levels
of Gabrb1 (aripiprazole: 125.7 ± 4.7%, p < 0.05; haloperidol: 135.2 ± 4.2%, p < 0.01),
whereas the mRNA levels of Gabrb2 and Gabrb3 were not significantly altered by any drug
administration (all p > 0.05) (Fig. 2A). In Western Blots, it was revealed that drug
administration significantly changed the levels of GABAA β-1 (F3, 20 = 7.627, p < 0.01) in the
NAc. Post-hoc tests demonstrated that administration with aripiprazole was able to elevate
significantly the levels of GABAA β-1 (164.3 ± 13.1%, p < 0.01) (Fig. 3A & 3C) in the NAc;
in addition, haloperidol showed trends to increase the expression of GABAA β-1 (126.1 ±
7.3%, p < 0.1) in the NAc. It is worth noting that the protein levels of GABAA β-1 was also
positively correlated with the levels of p-PKA (r = 0.691, p < 0.05) (Fig. 4A) and the ratio of
p-PKA/PKA (r = 0.583, p < 0.05) in the NAc (Fig. 4B). On the other hand, in the CPu,
neither the mRNA levels (Fig. 2B) nor the protein expression of the subunits of GABAA
receptors (Fig. 3B & 3D) were significantly altered by any antipsychotic drug.
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It was also observed that the mRNA expression levels of Creb1 (F3, 20 = 2.952, p < 0.05) were
significantly altered by antipsychotic drug administration in the NAc. Post-hoc tests indicated
that both aripiprazole and haloperidol administration significantly elevated the mRNA levels
of Creb1 (aripiprazole: 124.1 ± 5.3%, p < 0.05; haloperidol: 125.7 ± 7.7%, p < 0.01) in the
NAc (Fig. 2A). Western Blots indicated that drug administration significantly changed the
levels of CREB1 (F3,

20

= 3.656, p < 0.05) in the NAc. Post-hoc tests showed that

administration with aripiprazole was able to significantly promote the expression of CREB1
(127.4 ± 5.9%, p < 0.05) (Fig. 3A & 3C) in the NAc; additionally, haloperidol also elevated
the protein levels of CREB1, but did not reach significance (119.1 ± 6.7%, p < 0.1).
Moreover, the protein expression of CREB1 was positively correlated with the levels of pPKA (r = 0.371, p < 0.05) (Fig. 4C), as well as the ratio of p-PKA/PKA (r = 0.750, p < 0.01)
in the NAc (Fig. 4D). On the other hand, in the CPu, no drug administration significantly
changed either the mRNA levels of Creb1 (all p > 0.1) (Fig. 2B) or its protein expression (Fig.
3B & 3D).

Discussion
The present study measured the in vivo effects of antipsychotics on PKA signalling in the
PFC, NAc and CPu. We observed significant effects on PKA signalling induced by
aripiprazole and haloperidol in the NAc and CPu. Aripiprazole and haloperidol, but not
bifeprunox, activated PKA phosphorylation in the NAc. However, different effects were
observed in the CPu – aripiprazole, unlike haloperidol, inhibited PKA activity in the CPu.
Further analysis showed that mRNA expression and protein levels of GABAA receptors
(containing β-1 subunit) and CERB1 were up-regulated by both aripiprazole and haloperidol
administration, and were also significantly correlated with p-PKA levels and/or the ratios of
p-PKA/PKA in the NAc. This indicates that aripiprazole and haloperidol might up-regulate
11

the expression of GABAA and CREB1 through PKA signalling in the NAc. In the CPu, on
the other hand, unexpectedly, GABAA receptors and CREB1 were not significantly altered by
aripiprazole and haloperidol, although they changed the ratios of p-PKA/PKA.

The present study demonstrated that haloperidol enhanced PKA activity in the NAc and CPu
by increasing the levels of p-PKA and/or the ratio of p-PKA/PKA. Previously, a study
showed the protein levels of PKA-Cα were elevated in the CPu by acute administration with
haloperidol, but not in the PFC and NAc (Turalba et al., 2004). A long-term study revealed
that the activity of the cAMP-PKA pathway in the striatum was significantly increased after
administration with haloperidol for 3 weeks (Dwivedi et al., 2002). Our results are consistent
with those of previous studies, suggesting that haloperidol is able to antagonise D2-like
receptors to increase PKA signalling. Furthermore, our study is the first study to examine the
effects of aripiprazole; we found increased PKA phosphorylation levels and an increased
ratio of p-PKA/PKA in the NAc, which is similar to the effects of haloperidol in this brain
region, suggesting its antagonistic effects on D2-like receptors. It is interesting that
aripiprazole reduced the ratio of p-PKA/PKA in the CPu in the present study, whereas
haloperidol increased it. This reduction may indicate that aripiprazole exerts agonistic effects
on D2-like receptors together with endogenous dopamine in this brain region. Moreover,
aripiprazole is a functionally selective ligand for the dopamine D2 receptor (Han et al., 2009,
Mailman and Murthy, 2010). These opposite effects of aripiprazole on PKA signalling in the
NAc and CPu might be (at least partly) attributed to its functional selectivity for the D2
receptor. This may also explain why aripiprazole has fewer EPS side-effects than haloperidol,
since haloperidol can increase PKA signalling in both the NAc and CPu. Lastly, bifeprunox
had no effect on PKA activity in all brain regions in this study, probably because bifeprunox
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possesses a high level of intrinsic activity (Tadori et al., 2007), exhibiting overall agonistic
effects with endogenous dopamine.

We further observed that haloperidol enhanced PKA activity in the CPu. However,
aripiprazole reduced it by decreasing the ratio of p-PKA/PKA, probably due to its functional
selectivity for the D2 receptor, as discussed earlier. It was also revealed that aripiprazole may
act as a potent partial agonist, weak agonist, or antagonist depending upon the cellular
environments of the targeted D2 receptors (Burris et al., 2002, Kikuchi et al., 1995, Lawler et
al., 1999, Mailman and Murthy, 2010, Shapiro et al., 2003, Urban et al., 2007). It should be
noted that the NAc and CPu are heterogeneous structures with different connections with
various brain regions (reviewed by Yager et al., 2015). For example, the NAc receives
dopaminergic inputs from the ventral tegmental area (VTA) and links with limbic areas and
the PFC, while the CPu receives dopaminergic inputs from the substantia nigra pars (SN) and
links with neocortical areas, particularly the motor areas (Yager et al., 2015). Blockade of
dopamine D2 receptor activity in the mesolimbic (VTA–NAc) pathway is the common
mechanism of antipsychotic actions, particularly in the control of positive symptoms of
schizophrenia (Ginovart and Kapur, 2012); in addition, EPS side-effects induced by
antipsychotics are related to the blockade of D2 receptors in the nigrostriatal (SN–CPu)
pathway (Tauscher et al., 2002). Since the cellular environments are distinct between the
NAc and CPu, this theory of functional selectivity may be applied to the present study to
explain the regional differences of aripiprazole on PKA signalling. However, the previous
evidence was primarily based on in vitro studies (Burris et al., 2002, Kikuchi et al., 1995,
Lawler et al., 1999, Mailman and Murthy, 2010, Shapiro et al., 2003, Tadori et al., 2011,
Tadori et al., 2007, Tadori et al., 2005, Urban et al., 2007), and the in vivo effects of
aripiprazole require further investigation. Moreover, in view that the pathological changes in
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various mental disorders, the extra- and intra-cellular environments should be different in the
patients’ brains from those of the normal subjects. Therefore, it could be reasoned that
psychoactive drugs may affect the PKA signalling differently in patients or rodent models for
schizophrenia (such as the amphetamine and phencyclidine rat models, neuregulin-1 and
ErbB4 knock-out models for schizophrenia, etc.).

Hypofunction of dopamine signalling in the PFC has been found in schizophrenia subjects,
and it is believed that this hypofunction of dopamine signalling is connected with the
negative symptoms of schizophrenia (Howes and Kapur, 2009). Therefore, it can be assumed
that aripiprazole can exert agonistic effects on D2-like receptors under hypo-dopaminergic
conditions. Unexpectedly, we did not observe this agonistic effect in the PFC in the current
study. This study used healthy animals with normal dopamine signalling; in this situation, the
intrinsic activity of aripiprazole may not be potent enough to increase dopamine signalling
when it acts together with endogenous dopamine, so that we could not observe the agonistic
effect of aripiprazole while it happens under hypo-dopaminergic condition.

Previous evidence suggests that dysfunction in the GABA system is implicated in the
pathophysiology of schizophrenia (Lewis et al., 2004); and the GABAA receptor can be
regulated by D2-like receptor-mediated PKA signalling (Connelly et al., 2013, Poisbeau et al.,
1999). In this study, we found that both aripiprazole and haloperidol administration, but not
bifeprunox, were able to significantly increase mRNA expression of Gabrb1 in the NAc after
1-week administration, whereas in the CPu no alterations in the GABAA receptor were
induced by antipsychotic drug administration. In addition, both aripiprazole and haloperidol
elevated the protein expression of GABAA (containing β-1) receptor (although the increasing
effect of haloperidol did not reach significance). Previously, it is reported that chronic
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haloperidol administration increased the binding density of GABAA receptors in the NAc
(Zink et al., 2004), which is consistent with the finding of the present study. However, the
effects of antipsychotics on the GABAA receptor are quite brain region-dependent. Zink et al.
(2004) also revealed that haloperidol reduced GABAA receptor binding in the temporal and
parietal cortex, and both haloperidol and clozapine reduced it in the anterior cingulate and
infralimbic cortex. Additionally, 1-week administration with both haloperidol and olanzapine
increased the binding of GABAA receptors in the PFC (Skilbeck et al., 2007). Tanahashi et al.
(2012) and Peselmann et al. (2013) also suggested that aripiprazole affected GABA
signalling in a brain region-dependent manner.

In this study, both aripiprazole and haloperidol have the ability to facilitate PKA activity and
increase the levels of the GABAA receptor; we also revealed that the mRNA levels of
GABAA receptors are positively correlated with both the levels of p-PKA and the ratio of pPKA/PKA. It is therefore suggested that the regulation of GABAA receptors by
antipsychotics in the NAc might occur through regulating PKA signalling via D2-like
receptors. In addition, since dysfunction of the NAc is involved in the positive symptoms of
schizophrenia (Mikell et al., 2009) and the positive symptoms could be controlled by
blocking D2 receptors in NAc, our finding further suggests that PKA-GABAA signalling
transmission is very likely to be involved in the therapeutic effects of antipsychotics (possibly
in the positive symptoms of schizophrenia) (Fig. 5). On the other hand, antipsychotic
administration did not exert any effects on the GABAA receptor in the CPu, whereas
significant effects were revealed in the previous study after chronic haloperidol treatment
(Zink et al., 2004). This discrepancy may be due to the treatment period. It seems likely that
antipsychotic administration needs longer to exert a delayed effect on the GABAA receptor in
the CPu, but this requires further chronic study to validate.
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It should be noted that GABAA signalling was increased in various brain regions in
schizophrenia subjects in post-mortem studies (Benes et al., 1992, Benes et al., 1997, Dean et
al., 1999, Deng and Huang, 2006, Hanada et al., 1987, Ishikawa et al., 2004, Woo et al.,
2004) (although conflicting data existed (Pandey et al., 1997, Squires et al., 1993)). However,
our study exhibited increasing effects of antipsychotics on GABAA signalling in the NAc,
which was also reported by Zink et al., (2004). These findings conflict with the situation
observed in schizophrenia patients. Since most schizophrenia subjects have been exposed to
chronic antipsychotic treatment, the increased GABAA signalling observed in post-mortem
tissues might be at least partially a secondary effect of chronic antipsychotic treatment.
Additionally, there is no post-mortem data that directly describes the changes in GABAA
signalling in the NAc of schizophrenia patients, and further related studies are required to
address this issue.

Novel variants in the CREB gene have been identified in schizophrenic subjects (Kawanishi
et al., 1999, Shaywitz and Greenberg, 1999). CREB can be phosphorylated by PKA and
affected by antipsychotic administration (Dash et al., 1991). Previous studies reported that
haloperidol was able to increase phosphorylation levels of CREB both in vivo and in vitro
(Konradi and Heckers, 1995, Pozzi et al., 2003, Yang et al., 2004). In addition, atypical
antipsychotics amisulpride and clozapine can also induce phosphorylation of CREB in vitro
(Jeon et al., 2015, Park et al., 2011). The above antipsychotics are all D2R antagonists, which
may indicate that dis-inhibition of cAMP and activation of PKA via antagonising D2-like
receptors leads to increased activity of CREB. In the present study, administration with
haloperidol significantly increased mRNA expression of CREB1, as well as its protein
expression (tended to be significant), in the NAc, which is consistent with those previous
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findings (Konradi and Heckers, 1995, Pozzi et al., 2003, Yang et al., 2004). Our study is the
first study to examine the in vivo effects of D2 partial agonists (e.g. aripiprazole) on CREB so
far. We observed that aripiprazole had positive effects on elevating the protein expression and
mRNA levels of CREB1 in the NAc, whereas bifeprunox had no such effects. Since patients
with novel variants in the CREB gene experienced the positive symptoms of schizophrenia
(Kawanishi et al., 1999), up-regulation of CREB1 in the NAc is very likely to be associated
with the therapeutic effects of antipsychotics on the positive symptoms of schizophrenia. Fig.
5 depicts a proposed mechanism indicating that antipsychotics activate PKA signalling via
antagonising D2-like receptors, and might link to the increase in the expression of CREB1 to
exert therapeutic effects on the positive symptoms of schizophrenia.

It is worth noting that CREB activity can also be affected by the mitogen-activated protein
kinase (MAPK)/extracellular signal-regulated kinases (ERK) signalling cascade, and this
regulation plays a role in schizophrenia (Kyosseva et al., 1999). Previously, both ERK and
CREB activity were reported to be up-regulated by both haloperidol and risperidone (Yang et
al., 2004). Therefore, MAPK/ERK signalling cascade via D2-associated Gβγ protein is another
possible (probably indirect) signalling pathway by which aripiprazole and haloperidol
regulate CREB1 to achieve their therapeutic effects on the positive symptoms of
schizophrenia. Therefore, the role of MAPK/ERK-mediated CREB1 activity in the
antipsychotic treatment of schizophrenia is worthy exploring in the future.

In summary, the present study demonstrated that aripiprazole was able to increase the
expression of GABAA (containing β-1 subunit) receptor and CREB1 in the NAc, which were
significantly correlated with the enhanced PKA signalling. However, further studies are
important to validate whether aripiprazole affects GABAA receptors and CREB1 via D2R-
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mediated PKA pathway by (1) using specific D2R antagonists, such as L-741,626 in
combination with the antipsychotic drugs, (2) evaluating transcription factor phosphorylation,
and (3) inhibiting PKA signalling. This study also suggested that aripiprazole may have
functionally selective effects on the dopamine D2 receptor to differentially regulate PKA
signalling in the NAc and CPu. Further studies are required to explore what roles the upregulation of GABAA receptors and CREB1 induced by antipsychotics plays in the treatment
of schizophrenia. It is worthy noting that the present and previous studies mentioned above
examined the effects of antipsychotic drugs on the PKA-related signalling pathways only in
healthy animals. It is, therefore, necessary to investigate whether these drugs have similar
effects in the animal models for schizophrenia and other mental disorders in future studies.
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Figures:
Figure 1. Effects of three antipsychotics on PKA signalling.
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The effects of control (CON), aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL)
on PKA signalling were measured in the prefrontal cortex (A), nucleus accumbens (B) and
caudate putamen (C). The representative bands of Western blot are shown in (D). PKA-Cα
was quantified at 42kDa; p-PKA was quantified at 42kDa. The data were normalised by
taking the average value of the control group as 100% and expressed as mean ± S.E.M. (* p ≤
0.05, ** p < 0.01 vs the control)
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Figure 2. Effects of three antipsychotics on the mRNA levels of PKA downstream
targets.
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The effects of control (CON), aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL)
on the PKA downstream Gabrb1, Gabrb2, Gabrb3 and Creb1 were measured in the nucleus
accumbens (A) and caudate putamen (B). (* p ≤ 0.05, ** p < 0.01 vs the control)
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Figure 3. Effects of three antipsychotics on protein expression of PKA downstream
targets.
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The effects of control (CON), aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL)
on the GABAA β-1, β-2 and β-3 subunits, as well as CREB1, were measured in the nucleus
accumbens (NAc) (A) and caudate putamen (CPu) (B). The representative bands of Western
blot of the NAc and CPu are shown in (C) and (D), respectively. GABAA β-1, β-2 and β-3
subunits were quantified at 54, 59, 55 kDa, respectively. CREB1 was quantified at 40k Da. (*
p ≤ 0.05, ** p < 0.01 vs the control)
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Figure 4. Correlations between mRNA expression of Gabrb1 and Creb1 with the
activation of PKA signalling in the NAc.
(A)

(B)

r = 0.691, p < 0.05

(C)

r = 0.583, p < 0.05

(D)

r = 0.371, p < 0.05

r = 0.750, p < 0.01

The mRNA expression of Gabrb1 is positively correlated with the levels of p-PKA (A) and
the ratio of p-PKA/PKA (B) in the NAc. The mRNA expression of Creb1 is positively
correlated with the levels of p-PKA (C) and the ratio of p-PKA/PKA (D).
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Figure 5. Possible mechanisms of increased expression of GABAA and CREB1 by
antipsychotic drugs through D2-like receptor modulated PKA signalling in the nucleus
accumbens.
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D2-like receptor activation can be reduced by D2 receptor antagonists (e.g. haloperidol) and
D2 receptor partial agonists with low intrinsic activity (e.g. aripiprazole) (A), resulting in
decreased inhibition (indicated by “ X ”) of adenylyl cyclase (AC), followed by an increased
cAMP level and PKA activation (B). The activation of PKA signalling may lead to increased
expression of GABAA (β-1) receptors (C) and enhanced CREB1-dependent gene expression
(D), which might be involved in the therapeutic actions of antipsychotics.
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